doi: 39 Kasperczyk, S
[5] Additionally, some patients may experience changes in lipid profiles, liver enzymes, or kidney function markers as their metabolic health improves or if side effects such as dehydration from gastrointestinal symptoms develop
F., Yoza, B
The FDA Declines to Approve Bydureon, a New Once-Weekly GLP-1 Agonist by ben kozak Amylin Pharmaceuticals and Eli Lilly, the makers of Byetta, the first ever GLP-1 agonist, have teamed up again to develop a brand new GLP-1 agonist, which they have named Bydureon
The present clinical study does not support the concept of hepatic steatosis-induced resistance of AA catabolism to acute hyperglucagonemia
Dose Adjustment : If fatigue is severe or persistent, healthcare providers may consider slowing the dose-escalation schedule (FDA labeling allows for flexible titration with 2.5 mg increments no more frequently than every 4 weeks) or maintaining a lower maintenance dose that balances therapeutic benefit with tolerability
